Articles producció científica> Bioquímica i Biotecnologia

Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia

  • Identification data

    Identifier: imarina:6051403
    Authors:
    Ettcheto, MirenOlloquequi, JordiSanchez-Lopez, ElenaBusquets, OriolCano, AmandaRegina Manzine, PatriciaBeas-Zarate, CarlosCastro-Torres, Ruben DLuisa Garcia, MariaBullo, MonicaAuladell, CarmeFolch, JaumeCamins, Antoni
    Abstract:
    Benzodiazepines (BZDs) and Z-drugs are compounds widely prescribed in medical practice due to their anxiolytic, hypnotic, and muscle relaxant properties. Yet, their chronic use is associated with cases of abuse, dependence, and relapse in many patients. Furthermore, elderly people are susceptible to alterations in pharmacodynamics, pharmacokinetics as well as to drug interaction due to polypharmacy. These situations increase the risk for the appearance of cognitive affectations and the development of pathologies like Alzheimer's disease (AD). In the present work, there is a summary of some clinical studies that have evaluated the effect of BZDs and Z-drugs in the adult population with and without AD, focusing on the relationship between their use and the loss of cognitive function. Additionally, there is an assessment of preclinical studies focused on finding molecular proof on the pathways by which these drugs could be involved in AD pathogenesis. Moreover, available data (1990-2019) on BZD and Z-drug use among elderly patients, with and without AD, was compiled in this work. Finally, the relationship between the use of BZD and Z-drugs for the treatment of insomnia and the appearance of AD biomarkers was analyzed. Results pointed to a vicious circle that would worsen the condition of patients over time. Likewise, it put into relevance the need for close monitoring of those patients using BZDs that also suffer from AD. Consequently, future studies should focus on optimizing strategies for insomnia treatment in the elderly by using other substances like melatonin agonists, which is described to have a much more significant safety profile.
  • Others:

    Author, as appears in the article.: Ettcheto, Miren; Olloquequi, Jordi; Sanchez-Lopez, Elena; Busquets, Oriol; Cano, Amanda; Regina Manzine, Patricia; Beas-Zarate, Carlos; Castro-Torres, Ruben D; Luisa Garcia, Maria; Bullo, Monica; Auladell, Carme; Folch, Jaume; Camins, Antoni
    Department: Bioquímica i Biotecnologia
    URV's Author/s: Bulló Bonet, Mònica / Folch Lopez, Jaume
    Keywords: Sleep disturbance Risk factors Pharmacological-treatment Long-term use Insomnia Impairment Gabaergic deafferentation hypothesis Dementia Cognitive decline Cognition Clinical-practice guideline Benzodiazepines Amyloid-beta American academy Alzheimer's disease dementia cognition benzodiazepines alzheimer's disease
    Abstract: Benzodiazepines (BZDs) and Z-drugs are compounds widely prescribed in medical practice due to their anxiolytic, hypnotic, and muscle relaxant properties. Yet, their chronic use is associated with cases of abuse, dependence, and relapse in many patients. Furthermore, elderly people are susceptible to alterations in pharmacodynamics, pharmacokinetics as well as to drug interaction due to polypharmacy. These situations increase the risk for the appearance of cognitive affectations and the development of pathologies like Alzheimer's disease (AD). In the present work, there is a summary of some clinical studies that have evaluated the effect of BZDs and Z-drugs in the adult population with and without AD, focusing on the relationship between their use and the loss of cognitive function. Additionally, there is an assessment of preclinical studies focused on finding molecular proof on the pathways by which these drugs could be involved in AD pathogenesis. Moreover, available data (1990-2019) on BZD and Z-drug use among elderly patients, with and without AD, was compiled in this work. Finally, the relationship between the use of BZD and Z-drugs for the treatment of insomnia and the appearance of AD biomarkers was analyzed. Results pointed to a vicious circle that would worsen the condition of patients over time. Likewise, it put into relevance the need for close monitoring of those patients using BZDs that also suffer from AD. Consequently, future studies should focus on optimizing strategies for insomnia treatment in the elderly by using other substances like melatonin agonists, which is described to have a much more significant safety profile.
    Thematic Areas: Saúde coletiva Química Psicología Nutrição Neurosciences Medicina veterinaria Medicina ii Medicina i Interdisciplinar Geriatrics & gerontology Engenharias iv Educação física Cognitive neuroscience Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología Biodiversidade Aging
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 16634365
    Author's mail: monica.bullo@urv.cat jaume.folch@urv.cat
    Author identifier: 0000-0002-0218-7046 0000-0002-5051-8858
    Record's date: 2024-10-12
    Papper version: info:eu-repo/semantics/publishedVersion
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Frontiers In Aging Neuroscience. 11 (344): 344-
    APA: Ettcheto, Miren; Olloquequi, Jordi; Sanchez-Lopez, Elena; Busquets, Oriol; Cano, Amanda; Regina Manzine, Patricia; Beas-Zarate, Carlos; Castro-Torres, (2020). Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia. Frontiers In Aging Neuroscience, 11(344), 344-. DOI: 10.3389/fnagi.2019.00344
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2020
    Publication Type: Journal Publications
  • Keywords:

    Aging,Cognitive Neuroscience,Geriatrics & Gerontology,Neurosciences
    Sleep disturbance
    Risk factors
    Pharmacological-treatment
    Long-term use
    Insomnia
    Impairment
    Gabaergic deafferentation hypothesis
    Dementia
    Cognitive decline
    Cognition
    Clinical-practice guideline
    Benzodiazepines
    Amyloid-beta
    American academy
    Alzheimer's disease
    dementia
    cognition
    benzodiazepines
    alzheimer's disease
    Saúde coletiva
    Química
    Psicología
    Nutrição
    Neurosciences
    Medicina veterinaria
    Medicina ii
    Medicina i
    Interdisciplinar
    Geriatrics & gerontology
    Engenharias iv
    Educação física
    Cognitive neuroscience
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Biotecnología
    Biodiversidade
    Aging
  • Documents:

  • Cerca a google

    Search to google scholar